XNAS 05 May, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 8,224 | 71,776 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 09 Apr 2026 | 8,224 | 8,224 | - | 17.9 | 147,045 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 89.84 per share. | 09 Apr 2026 | 8,224 | 0 | - | 89.8 | 738,844 | Common Stock |
| Paula Soteropoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 31 Mar 2026 | 599 | 599 | - | 8.4 | 5,056 | Common Stock |
| Paula Soteropoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 599 | 599 | - | - | Stock Option (Right to Buy) | |
| Paula Soteropoulos | Director | Sale of securities on an exchange or to another person at price $ 80.11 per share. | 31 Mar 2026 | 599 | 0 | - | 80.1 | 47,986 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 31 Mar 2026 | 40,000 | 114,367 | - | 17.9 | 715,200 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 40,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 74,367 | 10,399 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 85.54 per share. | 31 Mar 2026 | 7,232 | 0 | - | 85.5 | 618,625 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 84.57 per share. | 31 Mar 2026 | 19,469 | 7,232 | - | 84.6 | 1,646,493 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 83.90 per share. | 31 Mar 2026 | 59,800 | 26,701 | - | 83.9 | 5,017,220 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 82.84 per share. | 31 Mar 2026 | 2,366 | 86,501 | - | 82.8 | 195,999 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 81.36 per share. | 31 Mar 2026 | 800 | 88,867 | - | 81.4 | 65,088 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 80.25 per share. | 31 Mar 2026 | 1,485 | 89,667 | - | 80.2 | 119,171 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 78.86 per share. | 31 Mar 2026 | 21,825 | 91,152 | - | 78.9 | 1,721,120 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Sale of securities on an exchange or to another person at price $ 78.33 per share. | 31 Mar 2026 | 1,390 | 112,977 | - | 78.3 | 108,879 | Common Stock |
| Ryan Savitz | EVP, CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 31 Mar 2026 | 74,367 | 74,367 | - | 8.4 | 627,657 | Common Stock |
| Paula Soteropoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 24 Mar 2026 | 27,594 | 27,594 | - | 8.4 | 232,893 | Common Stock |
| Paula Soteropoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2026 | 27,594 | 1,198 | - | - | Stock Option (Right to Buy) | |
| Paula Soteropoulos | Director | Sale of securities on an exchange or to another person at price $ 78.05 per share. | 24 Mar 2026 | 27,594 | 0 | - | 78.1 | 2,153,712 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 16 Mar 2026 | 5,592 | 65,292 | - | 17.9 | 99,985 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.70 per share. | 16 Mar 2026 | 59,700 | 59,700 | - | 6.7 | 399,990 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 5,592 | 269,408 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 59,700 | 41 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 122,918 | 59,741 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.70 per share. | 12 Mar 2026 | 122,918 | 122,918 | - | 6.7 | 823,551 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Sale of securities on an exchange or to another person at price $ 80.69 per share. | 12 Mar 2026 | 43,505 | 79,413 | - | 80.7 | 3,510,418 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Sale of securities on an exchange or to another person at price $ 81.74 per share. | 12 Mar 2026 | 65,517 | 13,896 | - | 81.7 | 5,355,360 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Sale of securities on an exchange or to another person at price $ 82.60 per share. | 12 Mar 2026 | 12,796 | 1,100 | - | 82.6 | 1,056,950 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Sale of securities on an exchange or to another person at price $ 83.38 per share. | 12 Mar 2026 | 200 | 900 | - | 83.4 | 16,676 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Sale of securities on an exchange or to another person at price $ 85.53 per share. | 12 Mar 2026 | 900 | 0 | - | 85.5 | 76,977 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 12 Mar 2026 | 10,000 | 43,682 | - | 21.8 | 217,700 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 80.71 per share. | 12 Mar 2026 | 15,852 | 27,830 | - | 80.7 | 1,279,415 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 81.75 per share. | 12 Mar 2026 | 23,465 | 4,365 | - | 81.8 | 1,918,264 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 83.38 per share. | 12 Mar 2026 | 200 | 300 | - | 83.4 | 16,676 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 82.66 per share. | 12 Mar 2026 | 3,865 | 500 | - | 82.7 | 319,481 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 10,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 17,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 16,182 | 63,818 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 85.53 per share. | 12 Mar 2026 | 300 | 0 | - | 85.5 | 25,659 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 12 Mar 2026 | 16,182 | 16,182 | - | 17.9 | 289,334 | Common Stock |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 12 Mar 2026 | 17,500 | 33,682 | - | 22.1 | 386,225 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 12,500 | 106,250 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 12 Mar 2026 | 12,500 | 33,830 | - | 22.1 | 275,875 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 81.48 per share. | 12 Mar 2026 | 33,830 | 0 | - | 81.5 | 2,756,468 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 7,998 | 3,998 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 5,000 | 71,184 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 8,332 | 54,174 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 12 Mar 2026 | 7,998 | 7,998 | - | 8.4 | 67,503 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 12 Mar 2026 | 5,000 | 12,998 | - | 17.9 | 89,400 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 12 Mar 2026 | 8,332 | 21,330 | - | 21.8 | 181,388 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 355,000 | 355,000 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | EVP, CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 45.18 per share. | 04 Dec 2025 | 20,000 | 0 | - | 45.2 | 903,600 | Common Stock |
| Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 04 Dec 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 20,000 | 84,766 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 13 Nov 2025 | 83,978 | 87,978 | - | 8.4 | 708,774 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 31,250 | 118,750 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 37,494 | 62,506 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 40,287 | 76,184 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 3,529 | 116,471 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 83,978 | 11,996 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 13 Nov 2025 | 109,031 | 4,000 | - | 38.1 | 4,158,442 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 13 Nov 2025 | 31,250 | 113,031 | - | 22.1 | 689,688 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 13 Nov 2025 | 37,494 | 81,781 | - | 21.8 | 816,244 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 13 Nov 2025 | 40,287 | 44,287 | - | 17.9 | 720,332 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.72 per share. | 13 Nov 2025 | 18,576 | 4,000 | - | 37.7 | 700,687 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 13 Nov 2025 | 42,765 | 22,576 | - | 37.0 | 1,584,016 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 35.80 per share. | 13 Nov 2025 | 26,166 | 65,341 | - | 35.8 | 936,743 | Common Stock |
| Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 13 Nov 2025 | 3,529 | 91,507 | - | 17.9 | 63,099 | Common Stock |
| Marino Garcia | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 20,000 | 104,766 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 09 Sep 2025 | 20,000 | 0 | - | 35 | 700,000 | Common Stock |
| Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 09 Sep 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Paula Soteropoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Steven Joseph Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Anne M. McGeorge | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Simon Read | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sujay R. Kango | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 340,000 | 340,000 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Steven Joseph Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Leon O. Moulder | Director | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | ||
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Paula Soteropoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 243,000 | 243,000 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Anne M. McGeorge | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Marino Garcia | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Savitz | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Leon O. Moulder | Director | 22 Jan 2024 | 166,667 | 1,436,745 | - | 12 | 2,000,004 | Common Stock | |
| Lei Meng | Director | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 22 Jan 2024 | 1,500,000 | 2,717,554 | - | 12 | 18,000,000 | Common Stock |
| Lei Meng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 1,833,333 | 1,833,333 | - | - | Pre-Funded Warrants (Right to Buy) |